Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

Blood Loss: full-pipeline trial registry

2 of 10 indexed Blood Loss trials are currently recruiting.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 2 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Blood Loss: 10 US clinical trials tracked, 2 recruiting.

Blood Loss is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Zynex Monitoring Solutions, running 1 of these trials.

Enrollment posture brief

Registry condition blood-loss

OPEN 2 | RECR 20% | LATE 3 | EARLY 4 | RANK #1724 | SPON 1

Nearest open-share peer: Acral Lentiginous Melanoma (20% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Blood Loss (this)20%
Open-enrollment share among volume-matched conditions near Blood Loss

Blood Loss lists 2 open slots (20% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Blood Loss on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Blood Loss is recruiting below its size-band peers.

    2 of 10 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Blood Loss trials is spread across many organizations.

    Zynex Monitoring Solutions accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Typical Blood Loss enrolment sits around 200 participants.

    Median target enrolment is 200 among the 10 trials that report a genuine target (sentinel values excluded). 3 of those (30%) plan for fewer than 100 participants.

  4. Blood Loss research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 24Phase 43

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 4 276 participants

Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

University of California, San Diego

NCT06820177

RECRUITING Phase 2 100 participants

Oxytocin Pharmacokinetics and Pharmacodynamics

University of Chicago

NCT05488457

ACTIVE NOT RECRUITING Phase 4 46 participants

Extended Postoperative Oral Tranexamic Acid in Knee Replacement

Campbell Clinic

NCT05099276

ACTIVE NOT RECRUITING NA 10 participants

LBNP Tolerance With Skin Warming After Exercise Cold Stress

University of Colorado, Colorado Springs

NCT06279897

COMPLETED Phase 4 400 participants

Oral Versus Intravenous Tranexamic Acid

Hospital for Special Surgery, New York

NCT04089865

COMPLETED NA 254 participants

Frozen Red Blood Cell Transfusions in Trauma Patients

Oregon Health and Science University

NCT01038557

COMPLETED Phase 2 243 participants

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT00888940

COMPLETED NA 200 participants

Clinical Evaluation of the CM-1500 in Postoperative Surgery Patients

Zynex Monitoring Solutions

NCT04706221

COMPLETED Phase 2 110 participants

Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery

University of Texas Southwestern Medical Center

NCT03856164

COMPLETED Phase 2 48 participants

Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation

University of Hawaii

NCT04651166

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 4 3

Named interventions

Most-linked intervention names on Blood Loss records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Tranexamic Acid Drug
3 trials
RBC units Biological
1 trials
Cyklokapron(R) Drug
1 trials
Ecallantide Drug
1 trials
CM-1500 Device
1 trials
Skin Surface Cooling Other
1 trials
Skin Surface Heating Other
1 trials

US sites by state

Facility locations filed on Blood Loss trials. A trial with sites in several states counts in each.

Texas 2 trials
California 2 trials
Tennessee 1 trials
Oregon 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Blood Loss page

10 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Blood Loss condition card totals 10 registered trials; most-linked intervention Placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.